Semax + Selank 10mg Neuropeptides

The combo rationale rests on a fundamental observation from thirty years of Russian clinical practice: Semax and Selank cover two complementary dimensions of the cognitive-emotional axis. Semax, derived from adrenocorticotropic hormone, is fundamentally nootropic and neurotrophic: potent BDNF and NGF induction, stimulation of selective attention, working memory consolidation, anti-ischemic neuroprotection documented in stroke trials. Selank, derived from endogenous tuftsin, is fundamentally anxiolytic and emotionally balancing: indirect GABAergic modulation without dependence or sedation, generalized anxiety relief, deep sleep regulation, immune modulation inherited from the parent peptide.

The Atlas Lab vial contains 5mg of each peptide, totaling 10mg of active neuropeptide principles, shipped lyophilized to guarantee maximum stability during transport and storage. Combo formulation optimizes the cost-efficiency ratio for research users wanting to explore the complete cognitive-emotional spectrum without multiplying separate vials.

In exploratory research, this sequential combination occupies a unique niche in the neuropeptide space: a "complete Russian stack" allowing simultaneous exploration of attentional, mnestic, anxiolytic, and emotional dimensions, with remarkable tolerance profile, no documented pharmacological tolerance, and no withdrawal syndrome. Russian clinical practice has established for over twenty years that sequential administration of Semax in the morning and Selank in late day generates an integrated action profile superior to isolated use of each molecule.

The Atlas Lab Semax+Selank 10mg combo vial contains 5mg of each peptide in a single lyophilized vial. Reconstitution uses 1 ml of bacteriostatic water to obtain a final concentration of 5 mg/ml of each peptide, totaling 10 mg/ml of total peptide. This "all-in-one" approach simplifies handling and reduces cost versus purchasing two separate vials, while guaranteeing perfectly coordinated simultaneous or sequential administration.

Research cyclesMost documented protocols are 10 to 21 consecutive days in active phase, followed by 2-to-4-week pause. Continuous administration beyond 30 days has not been studied in clinical trials and provides no demonstrated additional benefit on neurotrophic and behavioral biomarkers. For longitudinal evaluation, alternating 3 active weeks and 2 pause weeks over a 3-month horizon enables observation of cumulative structural effects while respecting neurotrophic pharmacology.

Essential chronobiologyImperatively respect the morning/evening gap between the two peaks to leverage complementary synergy. Administering both peptides simultaneously in the evening cancels much of the sequential benefit: Semax then needlessly stimulates noradrenergic tone when the organism prepares for sleep onset, and Selank arrives too early to cover the night. The most frequent user mistake is administering everything in the morning to simplify protocol: in that case, prefer purchasing peptides in separate vials.

Le flacon combo Semax+Selank 10mg se conserve entre 2 et 8 degres Celsius dans son emballage d'origine, a l'abri de la lumiere directe et de toute source d'humidite. Sous ces conditions optimales, un lyophilisat reste en général stable jusqu'à 24 mois. Le tripeptide C-terminal Pro-Gly-Pro partage par les deux molecules confere au combo une robustesse structurale superieure a la plupart des peptides de recherche, mais la forme lyophilisee reste sensible a l'humidite atmospherique: refermer soigneusement apres manipulation et eviter les ouvertures prolongees en environnement humide. Apres reconstitution avec 1 ml d'eau bacteriostatique (alcool benzylique 0,9 pour cent), la solution obtenue a 10 mg/ml total (5 mg/ml de chaque peptide) se conserve entre 2 et 8 degres Celsius pendant 30 a 60 jours avec une stabilite superieure a 95 pour cent pour chaque composant. Cette duree exceptionnelle reflet la stabilite intrinseque des deux heptapeptides, parmi les plus robustes de la chimie des peptides de recherche. Ne jamais congeler le flacon reconstitue: les cycles gel-degel generent une agregation partielle et une perte de 5 a 10 pour cent de bioactivite par cycle, sans distinction entre les deux peptides. Pour la formulation intranasale diluee dans NaCl 0,9 pour cent sans conservateur, la duree de conservation raccourcit a 7 a 10 jours au refrigerateur en raison du risque de contamination bacterienne. Utiliser preferentiellement des flacons spray sterilises et renouveler la preparation regulierement. Pour une conservation plus longue, ajouter du chlorure de benzalkonium 0,01 pour cent comme conservateur, pratique standard des formulations magistrales russes. A reception, controler l'integrite du pack froid et placer immediatement le flacon au refrigerateur. Une exposition breve a temperature ambiante lors du transport n'altere pas significativement la bioactivite du produit lyophilise grace a sa stabilite structurale inherente, mais prolonger cette exposition au-dela de 96 heures consecutives est deconseille. Ne jamais diluer le combo avec de l'eau non sterile, des solutions contenant des ions metalliques divalents en forte concentration (calcium, magnesium) pouvant affecter la conformation peptidique, ou des solutions tamponnees a pH fortement alcalin (au-dessus de 9) ou fortement acide (en dessous de 3). Les dilutions dans NaCl 0,9 pour cent, eau pour preparation injectable et eau bacteriostatique sont compatibles et recommandees.

Semax+Selank pharmacological synergy rests on the fine articulation of four converging and diverging mechanisms that explain why the combination generates a more complete profile than the simple sum of the two isolated molecules.

First axis, convergentShared enkephalinase inhibition (EC 3.4.24.11). Both peptides block this brain metallopeptidase that normally degrades endogenous enkephalins. This common mechanism prolongs enkephalin action in synaptic clefts and indirectly potentiates cortical dopaminergic and serotonergic systems. Administered separately, each molecule exerts this modest effect; administered sequentially across the day, they maintain continuous enkephalinase inhibition that stabilizes monoaminergic tone over 24 hours.

Third axis, divergentAutonomic system regulation. Semax slightly potentiates cortical noradrenergic activity, resulting in improved morning vigilance and possible transient blood pressure elevation in sensitive subjects. Selank conversely exerts vagotonic and GABAergic effect with modest decrease in blood pressure and heart rate. Administered in morning/evening sequence, this active/calm alternation respects natural circadian physiology and optimizes both daytime alertness and nighttime deep sleep.

Fourth axis, convergentNeuroinflammation and cytokines. Both peptides share documented brain anti-inflammatory action with reduction of pro-inflammatory cytokines IL-1 beta, TNF-alpha, and IL-6 in experimental models. This common property, inherited from their original neuroimmune dimension (ACTH for Semax, tuftsin for Selank), creates synergy in chronic neuroprotection against subclinical inflammatory aggressions linked to stress, aging, and incipient neurodegenerative pathologies.

The sequential administration pattern recommended in Russian literature exploits these four axes optimally. Semax in the morning initiates the day with neurotrophic and attentional stimulation without cortisol. Selank in late afternoon or early evening prepares the transition to relaxation by soothing residual noradrenergic tone, facilitating sleep onset and allowing Semax-induced BDNF to consolidate memory traces during deep slow-wave sleep. This chronobiological logic explains why Russian clinical practice adopted this sequential scheme as informal standard.

Scientific literature on combined Semax+Selank use is principally derived from Russian publications, with some integrative reviews accessible in English. Individual studies on each peptide are solid (Stroke 2000 for Semax, Front Pharmacol 2016 for Selank), while the combination has been subject of clinical protocols in several Moscow institutes without these results being systematically translated or published in high-impact international journals.

Gusev and Skvortsova (2000, Stroke, 31:1 pages 178-183) remain the Western reference on Semax alone in acute ischemic stroke. Volkova and colleagues (2016, Front Pharmacol) constitute the Western reference on Selank in generalized anxiety. Synthesis of these two clinical databases suggests the combination should exert individual benefits of both peptides without unfavorable pharmacodynamic interaction, the common enkephalinase-inhibition mechanism being moderate and divergent mechanisms (BDNF for Semax, GABAergic for Selank) not generating direct interaction.

Kolomin and colleagues (2012, Front Pharmacol, 3:42) published an English-language integrative review on both peptides and their molecular pathways, demonstrating each modifies expression of over 1,000 distinct brain genes, with significant overlap on synaptic plasticity and anti-inflammation pathways, and marked divergences on growth factor (Semax predominance) and GABAergic signaling (Selank predominance) pathways.